Suggestions

Du même auteur

Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study

Archive ouverte | Lepage, Côme | CCSD

International audience. Background: Following European guidelines, patients with aggressive metastatic or locally advanced, non-resectable, duodeno-pancreatic (DP) neuroendocrine tumours (NETs) should receive system...

Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort

Archive ouverte | Walter, T. | CCSD

IF 6.029. International audience. BackgroundDiagnosis and management of poorly differentiated gastro-entero-pancreatic (GEP) neuroendocrine carcinomas (NECs) remain challenging. Recent studies suggest prognostic het...

FFCD Prodige 31 Reminnet. FFCD Prodige 31 Reminnet: a european, multicentre, phase II/III randomized double-blind, placebo-controlled study evaluating. : lanreotide as maintenance therapy after first-line (1l) treatment in patients with non-resectableduodeno-pancreatic neuroendocrine

Archive ouverte | Lepage, Côme | CCSD

International audience

Chargement des enrichissements...